Naturemiri is developing microRNA inhibition strategies, both in the laboratory and the clinic. NaturemiRIâs patent-pending Plasmid-based MicroRNA Inhibitor System (PMIS) has been shown to be effective in both in vivo and in vitro models, and surmounts many of the obstacles researchers have faced with traditional MicroRNA inhibition approaches. The PMIS is the ONLY microRNA inhibitor that can be used to generate Transgenic Mice to understand the functions of microRNAs during development and as disease models. These animal models prove the Specificity, Efficacy and Non-Toxic effects of the PMIS in vivo. The firm has generated mouse models and stable PMIS expressing cell lines that allow for the discovery of new microRNA targets, processes, and pathways. PMIS libraries can be used to screen for drug interactions and disease causing molecular effects. It is currently testing the PMIS as a therapeutic biologic molecule in preclinical and human clinical trials for cancer, tissue/bone regeneration and arthritis
